Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

Nature Methods

Volumn 13, Issue 6, 2016, Pages 521-527

  Hafner, Marc ^a   Niepel, Mario ^a   Chung, Mirra ^a   Sorger, Peter K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BATIMASTAT; BIOLOGICAL MARKER; DOXYCYCLINE; ETOPOSIDE; LINSITINIB; METHOTREXATE; OLIGOMYCIN; PACLITAXEL; BIOLOGICAL PRODUCT; MOLECULAR LIBRARY;

ARTICLE; ARTIFACT; CANCER PATIENT; CELL DENSITY; DRUG SENSITIVITY; GENOTYPE; GROWTH RATE; HUMAN; HUMAN CELL; IC50; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; TUMOR CELL; CELL COUNT; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; COMPUTER SIMULATION; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; HIGH THROUGHPUT SCREENING; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES; THEORETICAL MODEL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CELL COUNT; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, THEORETICAL; SMALL MOLECULE LIBRARIES;

EID: 84965071035     PISSN: 15487091     EISSN: 15487105     Source Type: Journal    
DOI: 10.1038/nmeth.3853     Document Type: Article

References (43)

1. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
2. Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
3. Heiser, L.M. et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. USA 109, 2724-2729 (2012).
4. Schenone, M., Danc ík, V., Wagner, B.K., Clemons, P.A. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9, 232-240 (2013).
5. Cravatt, B.F., Gottesfeld, J.M. Chemical biology meets biological chemistry minireview series. J. Biol. Chem. 285, 11031-11032 (2010).
6. Fallahi-Sichani, M., Honarnejad, S., Heiser, L.M., Gray, J.W., Sorger, P.K. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 9, 708-714 (2013).
7. Sebaugh, J.L. Guidelines for accurate EC50/IC50 estimation. Pharm. Stat. 10, 128-134 (2011).
8. Rees, M.G. et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 12, 109-116 (2016).
9. Seashore-Ludlow, B. et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5, 1210-1223 (2015).
10. Errington, T.M. et al. An open investigation of the reproducibility of cancer biology research. eLife 3, e04333 (2014).
11. Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389-393 (2013).
12. Safikhani, Z. et al. Revisiting inconsistency in large pharmacogenomic studies. Preprint at http://dx.doi.org/10.1101/026153 (2015).
13. The Cancer Cell Line Encyclopedia Consortium & the Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets. Nature 528, 84-87 (2015).
14. O'Connor, P.M. et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285-4300 (1997).
15. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., Lowe, S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
16. Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005).
17. Muranen, T. et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21, 227-239 (2012).
18. Chabner, B.A., Allegra, C.J., Curt, G.A., Calabresi, P. in The Pharmacological Basis of Therapeutics 9th edn. (eds. Hardman, J., Limbird, L.) Ch. 51 (McGraw-Hill, 1996).
19. Baguley, B.C. et al. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur. J. Cancer 31A, 230-237 (1995).
20. Caplow, M., Shanks, J., Ruhlen, R. How taxol modulates microtubule disassembly. J. Biol. Chem. 269, 23399-23402 (1994).
21. Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11, 5678-5685 (2005).
22. Shi, J., Orth, J.D., Mitchison, T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res. 68, 3269-3276 (2008).
23. Gascoigne, K.E., Taylor, S.S. Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111-122 (2008).
24. Konecny, G.E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630-1639 (2006).
25. Moasser, M.M., Basso, A., Averbuch, S.D., Rosen, N. The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61, 7184-7188 (2001).
26. Chauffert, B. et al. New insights into the kinetic resistance to anticancer agents. Cytotechnology 27, 225-235 (1998).
27. Dimanche-Boitrel, M.T., Garrido, C., Chauffert, B. Kinetic resistance to anticancer agents. Cytotechnology 12, 347-356 (1993).
28. Garrido, C. et al. Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. Int. J. Cancer 61, 873-879 (1995).
29. Fang, Y., Sullivan, R., Graham, C.H. Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp. Cell Res. 313, 867-877 (2007).
30. Sorby, M., Ostman, A. Protein-tyrosine phosphatase-mediated decrease of epidermal growth factor and platelet-derived growth factor receptor tyrosine phosphorylation in high cell density cultures. J. Biol. Chem. 271, 10963-10966 (1996).
31. Kim, J.H., Kushiro, K., Graham, N.A., Asthagiri, A.R. Tunable interplay between epidermal growth factor and cell-cell contact governs the spatial dynamics of epithelial growth. Proc. Natl. Acad. Sci. USA 106, 11149-11153 (2009).
32. Curto, M., Cole, B.K., Lallemand, D., Liu, C.H., McClatchey, A.I. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J. Cell Biol. 177, 893-903 (2007).
33. Kaplan, P.L., Anderson, M., Ozanne, B. Transforming growth factor(s) production enables cells to grow in the absence of serum: an autocrine system. Proc. Natl. Acad. Sci. USA 79, 485-489 (1982).
34. Sero, J.E. et al. Cell shape and the microenvironment regulate nuclear translocation of NF-B in breast epithelial and tumor cells. Mol. Syst. Biol. 11, 790 (2015).
35. Orth, J.D. et al. Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res. 71, 4608-4616 (2011).
36. Yuan, H. et al. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N. Engl. J. Med. 367, 1220-1227 (2012).
37. Crystal, A.S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
38. Nam, H.S., Benezra, R. High levels of Id1 expression define B1 type adult neural stem cells. Cell Stem Cell 5, 515-526 (2009).
39. Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27, 851-857 (2009).
40. Boehm, J.S. et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129, 1065-1079 (2007).
41. Soumillon, M., Cacchiarelli, D., Semrau, S., van Oudenaarden, A., Mikkelsen, T.S. Characterization of directed differentiation by high-throughput single-cell RNA-Seq. Preprint at http://biorxiv.org/content/early/2014/03/05/003236 (2014).
42. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).
43. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).